Integrating Biotechnology into Translational Cancer Research

O. John Semmes, Ph.D.

Director

Cancer Biology and Infectious Disease Research Center Eastern Virginia Medical School Norfolk, VA

> Eastern Virginia Medical School Discovery Laboratory



TRANSLATIONAL RESEARCH PROGRAM



BIOMARKER DISCOVERY



"Fishing Expedition" Unbiased Discovery



"Maybe Peyton Manning is good at baseball" "Maybe my favorite gene is a biomarker" Targeted Discovery

Rational Design

 "Data Analysis"

Beer Server G3 designed by MM



"Systems Biology"

"Orthoganol Confirmation" "Death by Validation"



"Integromics"

CBIDRC Biotechnology Expertise

Genomics

Proteomics

Metabolomics

Example Technologies

- Glycoproteomics
- Imaging Mass Spectrometry
- Quality Human Tissues for PRoBE compliant study

Glycoproteomics



Rasman, R. Nature methods 2, 817 (2005)





Fuster MM, Nature review cancer 5, 526 (2005)

Can we identify a cell surface glycoprotein involved in metastatsis?

N2 versus ML2



- 1. Metabolic labeling and chemoselective conjugation "CLICK"
- 2. Affinity detection and enrichment of labeled cell-surface sialylated proteins.
- 3. Streptavidin-captured protein subjected to quantitative LC-MS/MS.

Imaging cell-surface sialylation with ManNaz and dcfb-65



A. Flow cytometry analysis of fluorescent labeling. grey histogram, untreated cells; yellow, SAv-A488 only; green, control ManNAc treated cells; red, ManNAz treated cells.

B. Microscopic analysis of fluorescent labeling on live cells.TO-RPO-3 was used to stain nuclei.

CDCP1 Subcellular Localization in PCa tissue



CDCP1 mAb 41-2

Characterization and Quantitation of Target Glycopeptides

How to overcome the "either peptides or sugars" technology barrier?

Peptide bonds are stronger and more uniform than glycanyl/glycyl bonds.

Application of MRM and QqQ technology

4000 Q-TRAP[™] System



Discovery and Diagnostics



Application of Imaging Mass Spectrometry to the Clinical Management of Prostate Cancer





Comparison of MALDI spectra acquired from LCM cells versus in-tact tissue. A) Representative spectra generated from 100 prostate adenocarcinoma cells microdissected and mounted onto the MALDI target. B) Representative spectra from the same tissue in an area of prostate adenocarcinoma collected via direct analysis of intact tissue.

Registering Expression Levels of Selected m/z to Tissue Grid Position







Evaluating The Utility of MEKK2 IHC For PCa Stage/Grade





MALDI-MSI (m/z 4355)





Area of intense staining



4355 sequence identified as MEKK2

MEKK2 is Over-expressed in Insignificant Disease

nt nt

Insignificant

Significant

Direct IMS Diagnostics or Standard IHC Diagnostics??



MALDI LASER



Pathology-Directed Discovery Process



Integration is Critical to Success in Translational Research



Genologics LIM System

CBIDRC RESOURCES

Clinical Sites

Dermatology Internal Medicine Ob/Gyn Otolaryngology Pathology Pediatrics Oncology Urology Surgery

Clinical Biorepository

Prostate, Breast, Bladder, Renal, H&N, Melanoma 36,000 serum 4,000 urine 1,700 plasma 7,000 frozen tissue 600 EPS

Study Compliance

35 Grant submissions* 26 approved IRB protocols 6 patents

> Informatics Infrastructure CAISIS Genologics EMR Portals



Molecular Pathology IHC/SlidePath Tissue processing LCM Tissue Staging





Routine histologyTwo cores per blockSix blocks per case

Twelve Core Prostate Biopsy



Cancer Biology and Infectious Disease Research Center

Director John Semmes, PhD

Investigators Rick Drake, PhD Aurora Kerscher, PhD Julius Nyalwidhe, PhD Raymond Lance, MD Dean Troyer, MD

Fellows/Students

Cindy Guo, PhD Lisa Cazares, PhD Lifang Yang, MD Tanya Burch, PhD Shamina Mitchell Krista White, PhD Breanne Grigch Tiffany Benzine

Staff

Barb Conyers MaryAnn Clements Jessica Abbate Tarek Kandil Brian Main Michael Ward Chris Wilkins Paige Miller Yvonne Oden Elizabeth Smith



Clinical Research Activity

Jennifer Taylor, RN, Senatra Laurie Jackson, RN, CRU, SMG